<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01130597</url>
  </required_header>
  <id_info>
    <org_study_id>RLY5016-204</org_study_id>
    <nct_id>NCT01130597</nct_id>
  </id_info>
  <brief_title>Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease</brief_title>
  <official_title>A Multicenter, Open-Label, Single-Arm Study to Evaluate a Titration Regimen for Patiromer in Heart Failure Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Relypsa, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Relypsa, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the feasibility of individualized titration of
      patiromer according to serum potassium. This study also assessed the safety and tolerability
      of patiromer and the effects of patiromer on serum potassium in heart failure (HF)
      participants with chronic kidney disease (CKD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label, single-arm study to evaluate a titration regimen for patiromer in
      approximately 63 HF participants with CKD receiving one or more of the following:
      angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), or
      beta blockers (BBs). This study was considered to be exploratory.

      Upon successful completion of screening evaluations (-10 to -5 days prior to enrollment), all
      eligible participants were assigned at Baseline (Day 0 visit) to an initial dose of patiromer
      (20 g/day) and spironolactone (25 mg/day).

      Study visits for enrolled participants were scheduled for Days 3, 7, 14, 21, 28, 35, 42, 49
      and 56. A follow-up visit occurred on Day 63.

      At selected study visits, patiromer or spironolactone doses may have been titrated. The study
      dosing algorithm was designed to maintain an individual's serum potassium value in the range
      of 4.0 - 5.1 mEq/L (based on local lab data).

      Any participant with a local laboratory serum potassium value &lt; 3.5 or &gt; 5.5 mEq/L on two
      consecutive scheduled study visits, despite titration of patiromer or spironolactone, were
      withdrawn from the study, permanently discontinued patiromer and spironolactone, and returned
      for a follow-up visit within 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Serum Potassium in the Range of 3.5 - 5.5 mEq/L at the End of Treatment</measure>
    <time_frame>56 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Potassium in the Range of 3.5 - 5.5 mEq/L at Week 4</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Potassium in the Range of 3.5 - 5.5 mEq/L at Week 8</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Potassium in the Range of 4.0 - 5.1 mEq/L at Week 4</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Potassium in the Range of 4.0 - 5.1 mEq/L at Week 8</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Potassium in the Range of 4.0 - 5.1 mEq/L at the End of Treatment</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Dose of Patiromer at End of Treatment</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Patiromer Uptitration</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Patiromer Downtitration</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to First Patiromer Dose Titration</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Patiromer Titrations</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Patiromer Dose at Week 1</measure>
    <time_frame>Up to Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Patiromer Dose at Week 4</measure>
    <time_frame>Up to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Patiromer Dose at Week 8</measure>
    <time_frame>Up to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Serum Potassium to End of Treatment</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Discontinuing Due to Hyperkalemia (Serum Potassium &gt; 5.5 mEq/L)</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Whose Spironolactone Dose Was Increased Up to 50 mg/Day</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urine Albumin to Creatinine Ratio (ACR) From Baseline to Week 4 Among Participants With ACR ≥ 30 mg/g at Baseline</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ACR From Baseline to Week 8 Among Participants With Urine ACR ≥ 30 mg/g at Baseline</measure>
    <time_frame>Baseline and Day 56</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>patiromer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>spironolactone + patiromer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>patiromer</intervention_name>
    <description>Active investigational drug</description>
    <arm_group_label>patiromer</arm_group_label>
    <other_name>RLY5016</other_name>
    <other_name>Veltassa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>spironolactone</intervention_name>
    <arm_group_label>patiromer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic HF clinically indicated to receive spironolactone therapy

          2. Age 18 years or older

          3. Local laboratory serum potassium values of 4.3 - 5.1 mEq/L at screening and baseline

          4. CKD (estimated glomerular filtration rate [eGFR] &lt; 60 mL/min/1.73m2 at screening based
             on central lab creatinine measurement)

          5. On at least one of the following HF therapies: ACEI, ARB, or BB

          6. Females of child-bearing potential must be non-lactating, must have a negative serum
             pregnancy test at screening, and must have used a highly effective form of
             contraception for at least 3 months before study drug administration, during the
             study, and for one month after study completion

          7. Male participants and/or their female partners of child-bearing potential must use a
             highly effective form of contraception during the study and for 3 months after study
             completion

          8. Provide their written informed consent prior to participation in the study

        Exclusion Criteria:

          1. History of bowel obstruction, swallowing disorders, severe gastrointestinal disorders
             or major gastrointestinal surgery

          2. Uncorrected primary severe valvular disease, known obstructive or restrictive
             cardiomyopathy, uncontrolled or hemodynamically unstable arrhythmia

          3. Coronary-artery bypass graft, percutaneous intervention (e.g., cardiac,
             cerebrovascular, aortic), or major surgery including thoracic and cardiac, within 3
             months prior to baseline or anticipated need during study participation

          4. Heart transplant recipient, or anticipated need for transplant during study
             participation

          5. Any of the following events having occurred within 2 months prior to baseline:
             unstable angina as judged by the Investigator, unresolved acute coronary syndrome,
             transient ischemic attack or stroke

          6. Current dialysis participant, or anticipated need for dialysis during study
             participation

          7. Prior kidney transplant, or anticipated need for transplant during study participation

          8. Metastatic, late-stage or end-stage cancer with &lt; 12 months life expectancy or at risk
             for tumor lysis syndrome

          9. History of alcoholism or drug/chemical abuse within 1 year

         10. Sustained systolic blood pressure &gt; 180 or &lt; 90 mmHg

         11. Liver enzymes [alanine aminotransferase (ALT), aspartate aminotransferase (AST)] &gt; 3
             times upper limit of normal

         12. Loop and thiazide diuretics that have not been stable for at least 21 days prior to
             baseline or not anticipated to remain stable during study participation

         13. Use of any intravenous cardiac medications within 21 days prior to baseline, or their
             anticipated need during study participation

         14. Current use of polymer-based drugs (e.g., sevelamer, sodium polystyrene sulfonate,
             colesevelam, colestipol), phosphate binders (e.g., lanthanum carbonate), or other
             potassium binders, or their anticipated need during study participation

         15. Use of potassium sparing medication including aldosterone antagonists or potassium
             supplements in the last 21 days prior to baseline

         16. Use of any investigational medication within 30 days or 5 half-lives, whichever is
             longer, prior to baseline

         17. Participants who have taken investigational product in this study, or a previous
             patiromer study

         18. Inability to consume the study medication, or, in the opinion of the Investigator,
             inability to comply with the protocol

         19. In the opinion of the Investigator, any medical condition, uncontrolled systemic
             disease, serious intercurrent illness, or extenuating circumstance occurring or
             persisting, within 30 days prior to baseline, that would significantly decrease study
             compliance or jeopardize the safety of the participant or affect the validity of the
             trial results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director Clinical Operations</last_name>
    <role>Study Director</role>
    <affiliation>Relypsa, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator Site 11</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 12</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 13</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 14</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 15</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 16</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 17</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 18</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 25</name>
      <address>
        <city>Golnik</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 27</name>
      <address>
        <city>Izola</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 21</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 22</name>
      <address>
        <city>Maribor</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 26</name>
      <address>
        <city>Slovenj Gradec</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Slovenia</country>
  </location_countries>
  <link>
    <url>http://www.relypsa.com</url>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>May 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <results_first_submitted>November 11, 2015</results_first_submitted>
  <results_first_submitted_qc>December 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 28, 2016</results_first_posted>
  <disposition_first_submitted>October 30, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>October 30, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 6, 2014</disposition_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HF</keyword>
  <keyword>Heart failure</keyword>
  <keyword>hyperkalemia</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>prevention of hyperkalemia in heart failure participants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Eligible participants were ≥ 18 years old, had a history of chronic HF, were clinically indicated to initiate spironolactone therapy, had a serum potassium measurement of 4.3 – 5.1 mEq/L at screening and baseline, had CKD (eGFR &lt; 60 mL/min/1.73 m2 at screening), and were taking one or more HF therapies (ACEIs, ARBs, or BBs).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Patiromer</title>
          <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol-specified (High K+)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patiromer</title>
          <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.8" lower_limit="53" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Serum Potassium in the Range of 3.5 - 5.5 mEq/L at the End of Treatment</title>
        <time_frame>56 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Potassium in the Range of 3.5 - 5.5 mEq/L at the End of Treatment</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Participants</param_type>
            <param_value>90.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80.4</ci_lower_limit>
            <ci_upper_limit>96.4</ci_upper_limit>
            <estimate_desc>Clopper-Pearson was used to arrive at the 95% Confidence Interval</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Potassium in the Range of 3.5 – 5.5 mEq/L at Week 4</title>
        <time_frame>28 Days</time_frame>
        <population>Participants with available data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Potassium in the Range of 3.5 – 5.5 mEq/L at Week 4</title>
          <population>Participants with available data at Week 4.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Potassium in the Range of 3.5 – 5.5 mEq/L at Week 8</title>
        <time_frame>56 Days</time_frame>
        <population>Participants with available data at Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Potassium in the Range of 3.5 – 5.5 mEq/L at Week 8</title>
          <population>Participants with available data at Week 8.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Potassium in the Range of 4.0 – 5.1 mEq/L at Week 4</title>
        <time_frame>28 Days</time_frame>
        <population>Participants with available data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Potassium in the Range of 4.0 – 5.1 mEq/L at Week 4</title>
          <population>Participants with available data at Week 4.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Potassium in the Range of 4.0 – 5.1 mEq/L at Week 8</title>
        <time_frame>56 Days</time_frame>
        <population>Participants with available data at Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Potassium in the Range of 4.0 – 5.1 mEq/L at Week 8</title>
          <population>Participants with available data at Week 8.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Potassium in the Range of 4.0 – 5.1 mEq/L at the End of Treatment</title>
        <time_frame>56 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Potassium in the Range of 4.0 – 5.1 mEq/L at the End of Treatment</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Participants</param_type>
            <param_value>84.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>72.7</ci_lower_limit>
            <ci_upper_limit>92.1</ci_upper_limit>
            <estimate_desc>Clopper-Pearson was used to arrive at the 95% Confidence Interval</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Dose of Patiromer at End of Treatment</title>
        <time_frame>56 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Dose of Patiromer at End of Treatment</title>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Patiromer Uptitration</title>
        <time_frame>56 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring Patiromer Uptitration</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Patiromer Downtitration</title>
        <time_frame>56 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring Patiromer Downtitration</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to First Patiromer Dose Titration</title>
        <time_frame>56 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to First Patiromer Dose Titration</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="14.0" upper_limit="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Patiromer Titrations</title>
        <time_frame>56 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Patiromer Titrations</title>
          <units>patiromer titrations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Patiromer Dose at Week 1</title>
        <time_frame>Up to Week 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Patiromer Dose at Week 1</title>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Patiromer Dose at Week 4</title>
        <time_frame>Up to Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Patiromer Dose at Week 4</title>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Patiromer Dose at Week 8</title>
        <time_frame>Up to Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Patiromer Dose at Week 8</title>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Serum Potassium to End of Treatment</title>
        <time_frame>56 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Serum Potassium to End of Treatment</title>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Discontinuing Due to Hyperkalemia (Serum Potassium &gt; 5.5 mEq/L)</title>
        <time_frame>56 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Discontinuing Due to Hyperkalemia (Serum Potassium &gt; 5.5 mEq/L)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Whose Spironolactone Dose Was Increased Up to 50 mg/Day</title>
        <time_frame>56 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Whose Spironolactone Dose Was Increased Up to 50 mg/Day</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urine Albumin to Creatinine Ratio (ACR) From Baseline to Week 4 Among Participants With ACR ≥ 30 mg/g at Baseline</title>
        <time_frame>Baseline and Day 28</time_frame>
        <population>Participants with urine ACR ≥ 30 mg/g at baseline and available data at Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urine Albumin to Creatinine Ratio (ACR) From Baseline to Week 4 Among Participants With ACR ≥ 30 mg/g at Baseline</title>
          <population>Participants with urine ACR ≥ 30 mg/g at baseline and available data at Week 4</population>
          <units>mg/g</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-291.01" spread="130.7973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ACR From Baseline to Week 8 Among Participants With Urine ACR ≥ 30 mg/g at Baseline</title>
        <time_frame>Baseline and Day 56</time_frame>
        <population>Participants with urine ACR ≥ 30 mg/g at baseline and available data at Week 8</population>
        <group_list>
          <group group_id="O1">
            <title>Patiromer</title>
            <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ACR From Baseline to Week 8 Among Participants With Urine ACR ≥ 30 mg/g at Baseline</title>
          <population>Participants with urine ACR ≥ 30 mg/g at baseline and available data at Week 8</population>
          <units>mg/g</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-291.06" spread="141.5644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 7 days after Day 56 or last patiromer dose, whichever was earlier.</time_frame>
      <desc>Participants who received at least one dose of trial medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Patiromer</title>
          <description>Spironolactone + Patiromer
Participants received patiromer (20 g/day, administered as a divided dose of 10 g in the morning and 10 g in the evening) and spironolactone (25 mg/day, administered once daily), orally. After Day 3, at the first occurrence of a serum potassium value of ≤ 5.1 mEq/L, the spironolactone dose was increased once to 50 mg/day; dose reductions were not allowed.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <description>Sudden death occurred during the follow up period, after completing the study.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Our agreements generally provide that PI cannot publish single site data before publication of the multi-site publication, unless 1 year has elapsed since completion of the study at all sites. Thereafter, PI may publish provided that PI shall: provide a copy of the publication to sponsor at least 60 days in advance of submission for publication; delete sponsor’s confidential information as requested; and delay publication up to an additional 90 days to permit protection of intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information</name_or_title>
      <organization>Relypsa, Inc.</organization>
      <phone>1-844-relypsa</phone>
      <email>medinfo@relypsa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

